SBK-002

1) To analyze the excretion pathway of [14C]sbk002 after oral administration to subjects; 2) To identify the main metabolites of [14C]sbk002 in the human body after oral administration to subjects; 3) To investigate the pharmacokinetics of total radioactivity after oral administration of [14C]sbk002 to subjects.

To evaluate the in vivo pharmacodynamic characteristics of the test preparation SBK002 tablets and the reference preparation clopidogrel bisulfate tablets (Plavix®) in healthy male subjects after multiple oral administration in the fasting state, and to assess the pharmacodynamic equivalence of the two preparations.